¹Mifepristone access is restricted by the FDA under the risk evaluation and mitigation strategy and approved through 70 d of gestation. Rules for its use are summarized here: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-20-weeks-gestation

¹Contraindications to methotrexate use include renal or hepatic disease, bone marrow dysfunction, active gastrointestinal or respiratory disease. Asthma is not a contraindication.

¹Do not use both together. Combining misoprostol and a Foley bulb does not improve vaginal delivery rates but does lead to more chorioamnionitis (Obstet Gynecol. 2020;136(5):953-961).

¹This is the recommendation from NICE and WHO. ACOG does not take an official position on continuous monitoring vs. intermittent auscultation. They note that continuous EFM does not affect perinatal death and cerebral palsy outcomes in low-risk pregnancies and cite a higher risk of c-section and operative vaginal deliveries with continuous EFM. They also recognize the need to adequately train staff in intermittent monitoring and the effect on staffing that the two approaches have.